Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel
Status:
Completed
Trial end date:
2017-03-08
Target enrollment:
Participant gender:
Summary
A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with
a native coronary stenosis suitable for DES implantation and OCT imaging are openly
randomized 1:1 to either BRILINTA™ (ticagrelor) or Plavix® (clopidogrel bisulfate).
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University The First Affiliated Hospital with Nanjing Medical University